Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS

Massimo Madonia; Antonio Murgia; Gianmarco Garau; Bruno Bussa; Pierluigi Caboni

doi:doi:10.11648/j.ijcu.20180201.11

| Peer-Reviewed

Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS

Massimo Madonia, Antonio Murgia, Gianmarco Garau, Bruno Bussa, Pierluigi Caboni

Published in International Journal of Clinical Urology (Volume 2, Issue 1)

Received: 17 May 2018 Accepted: 12 June 2018 Published: 6 July 2018

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Renal cell carcinoma (RCC) represent 2-3% of all cancers. Currently, there are no invasive screening tests that could help to find diagnosis and possible follow up in clinical practice. Most renal tumors are diagnosed by abdominal ultrasound (US) or contrast-enhanced (CT) performed for other medical reasons. In this work, the metabolite profile of urine of RCC samples, has been studied by gas chromatography coupled to mass spectrometry (GC-MS) and multivariate statistical data analysis. By the same means, differences between pathological and control samples were investigated. Results of discriminant analysis were studied with the aim to find possible relevant metabolites for each class. Palmitic acid, malic acid, allo-inositol, oleic acid and aspartic acid were up-regulated in pathological samples while psicose was down-regulated.

Published in	International Journal of Clinical Urology (Volume 2, Issue 1)
DOI	10.11648/j.ijcu.20180201.11
Page(s)	1-5
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2018. Published by Science Publishing Group

Keywords

Inositol, Aspartic Acid, GC-MS, Renal Cell Cancer

References

[1]	European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2. 3, 730 entity dictionary (2001), Lyon, 2001.
[2]	Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg. 2004; 93: 88.
[3]	Eble JN, Sauter G, Epstein JI (eds). In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.
[4]	Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein, JI, Grignon D et al. The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. The American journal of surgical pathology. 2013; 37(10): 1469-1489.
[5]	Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007; 26: 1346.
[6]	Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? EurUrol. 2010; 58: 588.
[7]	Jayson M, & Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998; 51: 203.
[8]	Hammers, H., Sternberg, C., Mcdermott, D. F., Larkin, J., Ravaud, A., Rini, B., A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus SunitinibMonotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. 2015; p. NCT02231749.
[9]	Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer. 2012; 107: 1131.
[10]	Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J ClinOncol. 2009; 27: 2645.
[11]	Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol. 2008; 180: 510.
[12]	Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25: 1603.
[13]	Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373: 1814.
[14]	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373: 1803.
[15]	Wahlgren T, Harmenberg U, Sandström P, Lundstam S, Kowalski J, Jakobsson, M, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer. 2013; 108: 1541.
[16]	Scano P, Murgia A, Pirisi F. M, Caboni P. A gas chromatography-mass spectrometry-based metabolomic approach for the characterization of goat milk compared with cow milk. J Dairy Sci. 2014; 97(10): 6057-6066.
[17]	Pisano MB, Scano P, Murgia A, Cosentino S, Caboni P. Metabolomics and microbiological profile of Italian mozzarella cheese produced with buffalo and cow milk. Food Chem. 2016; 192: 618-624.
[18]	Dessì A, Murgia A, Agostino R, Pattumelli MG, Schirru A, Scano P, et al. Exploring the Role of Different Neonatal Nutrition Regimens during the First Week of Life by Urinary GC-MS Metabolomics. Int. J. Mol. Sci. 2016; 17(2): 265.
[19]	Eriksson L, Byrne T, Johansson E, Trygg J, Vikström C. Multi-and megavariate data analysis basic principles and applications. 2013; Umetrics Academy.
[20]	Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A. An Integrated Metabolic Atlas of Clear Cell Renal Cell. Cancer cell. 2016; 29(1): 104-116.
[21]	Schieda N, Van der Pol CB, Moosavi B, McInnes MD, Mai KT, Flood TA. Intracellular lipid in papillary renal cell carcinoma (pRCC): T2 weighted (T2W) MRI and pathologic correlation. European radiology. 2015; 25(7): 2134-2142.
[22]	Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Mimi CY. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes & Control. 2002; 13(3): 287-293.
[23]	Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proceedings of the National Academy of Sciences. 2001; 98(6): 3387-3392.
[24]	Ooi A, Furge KA. Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and “cryptic targets” of transcription factors. Chinese journal of cancer. 2012; 31(9): 413.
[25]	Tan J, Yu CY, Wang ZH, Chen HY, Guan J, Chen YX, et al. Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer. Scientific reports. 2015; 5: 8473.

Cite This Article

Plain Text BibTeX RIS

APA Style

Massimo Madonia, Antonio Murgia, Gianmarco Garau, Bruno Bussa, Pierluigi Caboni. (2018). Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS. International Journal of Clinical Urology, 2(1), 1-5. https://doi.org/10.11648/j.ijcu.20180201.11

Copy | Download

ACS Style

Massimo Madonia; Antonio Murgia; Gianmarco Garau; Bruno Bussa; Pierluigi Caboni. Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS. Int. J. Clin. Urol. 2018, 2(1), 1-5. doi: 10.11648/j.ijcu.20180201.11

Copy | Download

AMA Style

Massimo Madonia, Antonio Murgia, Gianmarco Garau, Bruno Bussa, Pierluigi Caboni. Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS. Int J Clin Urol. 2018;2(1):1-5. doi: 10.11648/j.ijcu.20180201.11

Copy | Download

@article{10.11648/j.ijcu.20180201.11,
  author = {Massimo Madonia and Antonio Murgia and Gianmarco Garau and Bruno Bussa and Pierluigi Caboni},
  title = {Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS},
  journal = {International Journal of Clinical Urology},
  volume = {2},
  number = {1},
  pages = {1-5},
  doi = {10.11648/j.ijcu.20180201.11},
  url = {https://doi.org/10.11648/j.ijcu.20180201.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20180201.11},
  abstract = {Renal cell carcinoma (RCC) represent 2-3% of all cancers. Currently, there are no invasive screening tests that could help to find diagnosis and possible follow up in clinical practice. Most renal tumors are diagnosed by abdominal ultrasound (US) or contrast-enhanced (CT) performed for other medical reasons. In this work, the metabolite profile of urine of RCC samples, has been studied by gas chromatography coupled to mass spectrometry (GC-MS) and multivariate statistical data analysis. By the same means, differences between pathological and control samples were investigated. Results of discriminant analysis were studied with the aim to find possible relevant metabolites for each class. Palmitic acid, malic acid, allo-inositol, oleic acid and aspartic acid were up-regulated in pathological samples while psicose was down-regulated.},
 year = {2018}
}

Copy | Download

TY  - JOUR
T1  - Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS
AU  - Massimo Madonia
AU  - Antonio Murgia
AU  - Gianmarco Garau
AU  - Bruno Bussa
AU  - Pierluigi Caboni
Y1  - 2018/07/06
PY  - 2018
N1  - https://doi.org/10.11648/j.ijcu.20180201.11
DO  - 10.11648/j.ijcu.20180201.11
T2  - International Journal of Clinical Urology
JF  - International Journal of Clinical Urology
JO  - International Journal of Clinical Urology
SP  - 1
EP  - 5
PB  - Science Publishing Group
SN  - 2640-1355
UR  - https://doi.org/10.11648/j.ijcu.20180201.11
AB  - Renal cell carcinoma (RCC) represent 2-3% of all cancers. Currently, there are no invasive screening tests that could help to find diagnosis and possible follow up in clinical practice. Most renal tumors are diagnosed by abdominal ultrasound (US) or contrast-enhanced (CT) performed for other medical reasons. In this work, the metabolite profile of urine of RCC samples, has been studied by gas chromatography coupled to mass spectrometry (GC-MS) and multivariate statistical data analysis. By the same means, differences between pathological and control samples were investigated. Results of discriminant analysis were studied with the aim to find possible relevant metabolites for each class. Palmitic acid, malic acid, allo-inositol, oleic acid and aspartic acid were up-regulated in pathological samples while psicose was down-regulated.
VL  - 2
IS  - 1
ER  -

Copy | Download

Author Information

Massimo Madonia

Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
Antonio Murgia

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
Gianmarco Garau

Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
Bruno Bussa

Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
Pierluigi Caboni

Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Massimo Madonia, Antonio Murgia, Gianmarco Garau, Bruno Bussa, Pierluigi Caboni. (2018). Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS. International Journal of Clinical Urology, 2(1), 1-5. https://doi.org/10.11648/j.ijcu.20180201.11

Copy | Download

ACS Style

Massimo Madonia; Antonio Murgia; Gianmarco Garau; Bruno Bussa; Pierluigi Caboni. Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS. Int. J. Clin. Urol. 2018, 2(1), 1-5. doi: 10.11648/j.ijcu.20180201.11

Copy | Download

AMA Style

Massimo Madonia, Antonio Murgia, Gianmarco Garau, Bruno Bussa, Pierluigi Caboni. Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS. Int J Clin Urol. 2018;2(1):1-5. doi: 10.11648/j.ijcu.20180201.11

Copy | Download

@article{10.11648/j.ijcu.20180201.11,
  author = {Massimo Madonia and Antonio Murgia and Gianmarco Garau and Bruno Bussa and Pierluigi Caboni},
  title = {Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS},
  journal = {International Journal of Clinical Urology},
  volume = {2},
  number = {1},
  pages = {1-5},
  doi = {10.11648/j.ijcu.20180201.11},
  url = {https://doi.org/10.11648/j.ijcu.20180201.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20180201.11},
  abstract = {Renal cell carcinoma (RCC) represent 2-3% of all cancers. Currently, there are no invasive screening tests that could help to find diagnosis and possible follow up in clinical practice. Most renal tumors are diagnosed by abdominal ultrasound (US) or contrast-enhanced (CT) performed for other medical reasons. In this work, the metabolite profile of urine of RCC samples, has been studied by gas chromatography coupled to mass spectrometry (GC-MS) and multivariate statistical data analysis. By the same means, differences between pathological and control samples were investigated. Results of discriminant analysis were studied with the aim to find possible relevant metabolites for each class. Palmitic acid, malic acid, allo-inositol, oleic acid and aspartic acid were up-regulated in pathological samples while psicose was down-regulated.},
 year = {2018}
}

Copy | Download

TY  - JOUR
T1  - Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS
AU  - Massimo Madonia
AU  - Antonio Murgia
AU  - Gianmarco Garau
AU  - Bruno Bussa
AU  - Pierluigi Caboni
Y1  - 2018/07/06
PY  - 2018
N1  - https://doi.org/10.11648/j.ijcu.20180201.11
DO  - 10.11648/j.ijcu.20180201.11
T2  - International Journal of Clinical Urology
JF  - International Journal of Clinical Urology
JO  - International Journal of Clinical Urology
SP  - 1
EP  - 5
PB  - Science Publishing Group
SN  - 2640-1355
UR  - https://doi.org/10.11648/j.ijcu.20180201.11
AB  - Renal cell carcinoma (RCC) represent 2-3% of all cancers. Currently, there are no invasive screening tests that could help to find diagnosis and possible follow up in clinical practice. Most renal tumors are diagnosed by abdominal ultrasound (US) or contrast-enhanced (CT) performed for other medical reasons. In this work, the metabolite profile of urine of RCC samples, has been studied by gas chromatography coupled to mass spectrometry (GC-MS) and multivariate statistical data analysis. By the same means, differences between pathological and control samples were investigated. Results of discriminant analysis were studied with the aim to find possible relevant metabolites for each class. Palmitic acid, malic acid, allo-inositol, oleic acid and aspartic acid were up-regulated in pathological samples while psicose was down-regulated.
VL  - 2
IS  - 1
ER  -

Copy | Download